Combining epigenetic drugs with PARP inhibitors for ovarian cancer treatment
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
This study is looking at whether combining certain cancer drugs can help improve treatment for women with ovarian cancer that doesn't respond well to regular chemotherapy, especially for those with specific tumor types.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10794977 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of combining poly ADP ribose polymerase inhibitors (PARPi) with various epigenetic drugs to improve treatment outcomes for patients with homologous recombination proficient ovarian cancer. The study focuses on patients whose cancer does not respond well to standard chemotherapy, particularly those with BRCA wild-type tumors. By using a combination of drugs that target different pathways, the research aims to create a more effective treatment regimen. The approach is based on preclinical findings that suggest these combinations can mimic the effects of treatments that work well for BRCA mutant cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with homologous recombination proficient ovarian cancer, particularly those with poor prognostic features such as CCNE1 amplification.
Not a fit: Patients with BRCA mutant ovarian cancer or those whose cancer has already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with hard-to-treat ovarian cancer, potentially improving their prognosis and quality of life.
How similar studies have performed: Other research has shown promising results with similar drug combination strategies in treating various cancers, indicating potential for success in this approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Khabele, Dineo — Washington University
- Study coordinator: Khabele, Dineo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.